GLP-1 Delayed Gastric Emptying: What’s Normal, What’s Not, and What to Do

The 60-second answer

GLP-1 delayed gastric emptying means your stomach is releasing food into the small intestine more slowly than usual. That slowing is not a malfunction — it’s a designed effect of every drug in this class, and it’s a big part of why Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, and the newly approved Foundayo reduce appetite and blunt blood sugar spikes.

For most people the effect is moderate. The largest meta-analysis to date (Hiramoto et al., 2024,Am J Gastroenterol) pooled five gastric emptying scintigraphy studies and found a solid-meal half-emptying delay of 36.0 minutes versus placebo — meaningful, but small relative to a normal 6–8 hour pre-op fast. The slowing is strongest in the first weeks and partially adapts with continuous use.

Three things change the answer:

1. Severity. Persistent vomiting, dehydration, severe pain, or vomiting food from hours earlier is not “the medication working.” That’s a call-your-clinician day.
2. Procedures. The picture changed in March 2026: the OCULUS randomized trial found patients who continued their GLP-1 before upper endoscopy without a clear-liquid prep had a 25% rate of clinically significant retained gastric volume vs 3.1% in those who held one dose — but in the subgroup that combined endoscopy with colonoscopy bowel prep, neither group had retained contents. Procedure prep matters as much as the drug decision.
3. Oral medications. Tirzepatide and Foundayo have specific birth-control timing rules in their FDA labels. Most people aren’t told this at the pharmacy.

The rest of this page sorts you into the right lane, gives you a printable note for your clinician or anesthesia team, and ends the search.

What to do right now: the action table

Find your situation, take the next step:

What does GLP-1 delayed gastric emptying actually mean?

Quick answer: Delayed gastric emptying means food leaves your stomach more slowly than baseline. Semaglutide, liraglutide, dulaglutide, and orforglipron are GLP-1 receptor agonists. Tirzepatide is a dual GIP/GLP-1 receptor agonist, activating a second receptor on top of the GLP-1 one. All of them slow gastric emptying as part of how they work.

How it actually works

Every time you eat, your gut releases a hormone called GLP-1(glucagon-like peptide-1). It tells your pancreas to release insulin, tells your brain you’re full, and tells your stomach to slow down so glucose enters your bloodstream gradually instead of all at once. Natural GLP-1 lasts about 2–3 minutes — broken down almost instantly. GLP-1 medications are engineered versions with the breakdown blocked. They keep the signal going for hours (short-acting) or days (long-acting weekly injectables like semaglutide and tirzepatide).

So when someone says “the GLP-1 is slowing my stomach”, they’re really saying:the medication is doing exactly what it’s designed to do.

Short-acting vs. long-acting matters more than you think

• Short-acting GLP-1s (twice-daily exenatide, lixisenatide) cause stronger acute slowing because their levels swing up and down between doses.
• Long-acting GLP-1s (weekly semaglutide, weekly tirzepatide, weekly dulaglutide, daily liraglutide, daily oral semaglutide, daily orforglipron) cause an initial strong slowing that partially diminishes over weeks as your body adapts. The tirzepatide and Foundayo labels both specifically state the gastric-emptying delay is largest after the first dose and diminishes over time — that wording is right out of the FDA prescribing information.

A quick translator for the words floating around

If you remember one thing: “my stomach feels slow” is a symptom; “I have gastroparesis” is a diagnosis. They are not interchangeable, and the difference matters for what you do next.

Is what you’re feeling normal — or a red flag?

Quick answer: Mild fullness, reduced hunger, occasional nausea after a dose change, and softer stools or mild constipation are common during initiation and dose escalation, and often ease as the dose stabilizes. Persistent vomiting, severe abdominal pain, dehydration, inability to keep liquids down, or vomiting undigested food from hours earlier warrant a same-day call.

The honest version: most users will have some GI symptoms, most will be mild-to-moderate, most will improve with time and dietary tweaks, and a small minority will need real intervention. Knowing which lane you’re in is the whole game.

The self-check

The four things you should not do

• ⚠Don’t keep increasing your dose through severe GI symptoms.
• ⚠Don’t restart at your old high dose after a break without prescriber guidance — the gastric-slowing effect is back to “first dose” intensity.
• ⚠Don’t self-diagnose gastroparesis based on a TikTok or a Reddit thread.
• ⚠Don’t hide your GLP-1 from your surgery, anesthesia, or ER team. Ever.

Delayed gastric emptying vs. gastroparesis — they’re not the same

Quick answer: Delayed gastric emptying is a measurable slowing on a spectrum. Gastroparesis is a clinical diagnosis that requires significantly delayed emptying plus persistent symptoms plus the absence of a mechanical obstruction. Most people on a GLP-1 have some delayed gastric emptying. Few develop true gastroparesis.

How gastroparesis is actually diagnosed

The standard test is gastric emptying scintigraphy — you eat a small meal containing a trace amount of radioactive material, then a scanner tracks how quickly food leaves your stomach over four hours. The diagnostic criteria are concrete:

• More than 60% of the meal retained at 2 hours, or
• More than 10% retained at 4 hours

…plus persistent upper-GI symptoms (nausea, vomiting, early fullness, abdominal pain) typically lasting weeks, plus exclusion of mechanical causes like obstruction or ulcer disease.

Can I take a GLP-1 if I already have gastroparesis?

Risk factors for drug-induced gastroparesis

• Pre-existing diabetes-related neuropathy
• Maximum doses
• Rapid dose-escalation schedules
• Prior GI motility issues
• Prior abdominal surgery affecting the vagus nerve

If you don’t have any of those and your symptoms are mild, the math is reassuring. If you have any of those and your symptoms are severe, call your prescriber.

How long does the effect last? (Drug-by-drug, in real numbers)

Quick answer: While you’re on the drug, slowing happens with every dose but partially adapts over weeks of continued use. After stopping, the medication takes roughly 4–5 half-lives to clear — about 5 weeks for semaglutide, 3 weeks for tirzepatide, 5–10 days for Foundayo, and about 3 days for liraglutide. Gastric motility generally normalizes as drug levels fall.

Last verified April 25, 2026. Sources: current FDA prescribing information for each drug (accessdata.fda.gov, DailyMed), the 2024 multi-society perioperative guidance, the 2025 SPAQI consensus statement, and the Hiramoto et al. meta-analysis (Am J Gastroenterol, 2024). Verify each row against the live FDA label before relying on it for a clinical decision; we re-verify quarterly and after any major label revision.

The 2026 GLP-1 Delayed Gastric Emptying Reference Table

Surgery, colonoscopy, anesthesia: what current guidance actually says

Quick answer: Recommendations have evolved fast. The 2023 ASA advice was a blanket “hold for a week.” The October 2024 multi-society guidance shifted to risk stratification and a 24-hour clear-liquid diet. The 2025 SPAQI consensus refined fasting protocols. And in March 2026, the OCULUS randomized clinical trial showed that a clear-liquid prep day before upper endoscopy was the decisive factor — patients who continued their GLP-1 and had bowel prep had no clinically significant retained gastric volume. Tell your procedure team your drug, dose, and last dose date.

Guidance evolution at a glance

Procedure-specific notes

• Upper endoscopy / EGD:Highest concern. The 2026 OCULUS trial showed a 46.7% clinically significant residual gastric volume rate in the EGD-only continue-medication arm without a clear-liquid prep. With a clear-liquid prep day, both arms had 0%. If you’re not doing the prep day, the case for holding one dose is now stronger.
• Colonoscopy:Bowel prep already requires 24+ hours of clear liquids. Most colonoscopy patients on GLP-1s can continue — but tell your GI team in case they want to adjust the prep protocol.
• General surgery / general anesthesia:Decision belongs to your anesthesia team. Bring the script below.
• Emergency surgery:Treated as “full stomach” regardless of GLP-1 status. Standard rapid sequence induction protocols apply. You don’t have a decision to make here; the team does.

Who counts as “higher risk”

• Active dose escalation (vs. stable maintenance for months)
• Maximum dose
• Current GI symptoms in the 24–48 hours before the procedure
• Pre-existing gastroparesis or another motility disorder
• Upper endoscopy specifically (where retained gastric contents are most consequential)

Your printable conversation script for the pre-op visit

Copy this, fill in the blanks, and bring it to your pre-op screening:

Birth control, oral medications, and absorption: the part nobody warned you about

Quick answer: Several GLP-1 labels warn that delayed gastric emptying may affect oral medication absorption — and two of them have specific birth-control timing rules buried in the prescribing information. Tirzepatide (Zepbound, Mounjaro): use a non-oral or backup contraceptive method for 4 weeks after starting and after each dose escalation. Foundayo (orforglipron, FDA-approved April 2026): 30 days after starting and after each dose escalation. Most patients don’t get told this clearly. Now you have been.

Label-specific oral medication rules

Other oral medications worth a pharmacist conversation

The shorter the therapeutic window of a drug, the more delayed gastric emptying matters:

• Levothyroxine (Synthroid) — narrow therapeutic window; absorption is sensitive to timing and food
• Warfarin — narrow therapeutic window; routinely monitored, but tell your INR clinic about the GLP-1
• Anti-seizure medications — narrow therapeutic windows
• Transplant immunosuppressants — narrow therapeutic windows; coordinate with transplant team
• Diabetes medications (especially sulfonylureas and insulin) — risk of hypoglycemia changes when you eat less
• Digoxin — narrow therapeutic window
• Simvastatin with Foundayo specifically — Foundayo’s label limits simvastatin to 20 mg/day with concomitant use, even when dosing is staggered by 2 hours

Copyable question for your pharmacist. Takes about 90 seconds to answer and prevents a whole class of problems.

How to manage the symptoms day-to-day

Quick answer: For mild-to-moderate symptoms, smaller and lower-fat meals, slower bites, steady hydration between meals (not all at once), staying upright after eating, and slower dose escalation usually do more than any prescription remedy. This isn’t a gastroparesis diet — most users on a GLP-1 don’t need that level of restriction.

When dose adjustment makes more sense than pushing through

• Symptoms worsening rather than stabilizing
• New severe symptoms specifically after a dose increase (consider stepping back down)
• Inability to maintain adequate nutrition or hydration
• Symptoms that feel different from typical GI side effects — severe pain, fever, blood — warrant evaluation regardless of dose strategy

Most prescribers will hold or back-titrate a dose without drama. The ones who won’t aren’t the ones you want. See also: our guide to managing GLP-1 fatigue and GLP-1 constipation relief.

Is the effect permanent? What happens after you stop?

Quick answer: For most users, the gastric-slowing effect is reversible. As the medication clears (about 4–5 half-lives — roughly 3 weeks for tirzepatide, 5 weeks for semaglutide, 5–10 days for Foundayo, 3 days for liraglutide), gastric emptying generally normalizes. If symptoms persist beyond the expected clearance window, that warrants clinical evaluation.

The typical post-discontinuation timeline (semaglutide example)

• Weeks 1–2: Drug levels still high. Slowing continues. Hunger still suppressed. You don’t feel much different yet.
• Weeks 3–4: Drug levels falling. Fullness eases. “Food noise” starts coming back. Some people notice cravings returning by week 4.
• Weeks 5–6: Drug effectively cleared. Gastric motility usually back to baseline. Hunger and meal-size preferences typically normalize.

For tirzepatide, compress that timeline by ~40% (clearance is faster). For Foundayo, faster still — most of the effect should fade within 5–10 days. For liraglutide, it’s mostly resolved within days. For exenatide ER, it takes longer (6–10 weeks for full clearance).

When persistent post-stopping symptoms warrant evaluation

If GI symptoms haven’t improved 4–8 weeks after the drug should be cleared, talk to a clinician. Possible explanations include:

• Pre-existing motility disorder that was masked or made worse by the drug
• Diabetes-related neuropathy
• A separate, unrelated GI condition that happened to start during the same period
• Functional dyspepsia
• Less common causes that warrant proper workup

Don’t assume “the drug broke me.” It’s much more often that a separate condition is contributing — and that’s diagnosable and treatable.

Compounded vs. FDA-approved GLP-1s: what changes for delayed gastric emptying?

Quick answer: Compounded semaglutide and tirzepatide are not FDA-approved products, are not covered by FDA prescribing information, and have not undergone FDA premarket review for safety, quality, or effectiveness. We don’t claim equivalence between compounded and FDA-approved products.

What FDA has specifically said

• Compounded drugs are not FDA-approved and have not undergone FDA review for safety, quality, or effectiveness.
• FDA has issued warnings about dosing errors with compounded injectable semaglutide, including reports of adverse events and hospitalizations tied to measurement mistakes.
• FDA has warned about illegally marketed and counterfeit GLP-1 products, which may contain wrong, harmful, too little, too much, or no active ingredient.
• FDA has issued enforcement-related letters to telehealth companies regarding the marketing of compounded GLP-1s.

What to do if you’re using a compounded product

• Tell every clinician — and especially every anesthesia team — exactly what you’re taking. Don’t say “Ozempic” if you’re on compounded semaglutide.
• Verify the prescribing clinician (real licensure, real practice) and the dispensing pharmacy (name, state license, ideally outsourcing-facility status).
• Confirm dose units in the syringe (not just the dose label) — this is where reported dosing errors happen.
• Know the program’s protocol for vomiting, dehydration, severe symptoms, or unexpected events.
• Understand whether the program screens for gastroparesis or severe GI history before starting.

Honest limitation: On a medical safety page, we lean toward FDA-approved options where the label warnings, prescribing information, and post-market surveillance are most defensible. If a compounded path is the right fit for your situation, our best compounded semaglutide guide discusses both lanes with verification timestamps.

When to message your prescriber, when to switch, when to seek urgent care

Frequently asked questions

Still figuring out your GLP-1 path?